Eosinophil as a Protective Cell in S. aureus Ventilator-Associated Pneumonia by Rodríguez Fernández, Ana et al.
Hindawi Publishing Corporation
Mediators of Inflammation
Volume 2013, Article ID 152943, 5 pages
http://dx.doi.org/10.1155/2013/152943
Research Article
Eosinophil as a Protective Cell in S. aureus
Ventilator-Associated Pneumonia
Ana Rodriguez-Fernandez,1 David Andaluz-Ojeda,2 Raquel Almansa,1,3
Mar Justel,1 Jose Maria Eiros,1 and Raul Ortiz de Lejarazu1,4
1 Microbiology Service, Clinical University Hospital-SACYL, Avda Ramo´n y Cajal 3, 47005 Valladolid, Spain
2 Critical Care Medicine Service, Clinical University Hospital-SACYL, Avda Ramo´n y Cajal 3, 47005 Valladolid, Spain
3 Biomedical Investigation Unit, Clinical University Hospital (ibC), SACYL & IECSCYL, Avda Ramo´n y Cajal 3,
47005 Valladolid, Spain
4National Centre of Influenza, Avda Ramo´n y Cajal 7, 47005 Valladolid, Spain
Correspondence should be addressed to Ana Rodriguez-Fernandez; a.rodfer@hotmail.es
Received 30 July 2013; Accepted 30 July 2013
Academic Editor: Jesu´s F. Bermejo-Martin
Copyright © 2013 Ana Rodriguez-Fernandez et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Cell counts of leukocytes subpopulations are demonstrating to have an important value in predicting outcome in severe infections.
We evaluated here the render of leukogram counts to predict outcome in patients with ventilator-associated pneumonia (VAP)
caused by Staphylococcus aureus. Data from patients admitted to the ICU of Hospital Cl´ınico Universitario de Valladolid from
2006 to 2011 with diagnosis of VAP caused by S. aureuswere retrospectively collected for the study (𝑛 = 44). Leukocyte counts were
collected at ICU admission and also at VAPdiagnosis. Our results showed that nonsurvivors had significant lower eosinophil counts
at VAP diagnosis. Multivariate Cox regression analysis performed by the Wald test for forward selection showed that eosinophil
increments from ICU admission to VAP diagnosis and total eosinophil counts at VAP diagnosis were protective factors against
mortality in the first 28 days following diagnosis: (HR [CI 95%], 𝑃): (0.996 [0.993–0.999], 0.010); (0.370 [0.180–0.750], 0.006).
Patients with eosinophil counts <30 cells/mm3 at diagnosis died earlier. Eosinophil counts identified survivors: (AUROC [CI 95%],
𝑃): (0.701 [0.519–0.882], 0.042). Eosinophil behaves as a protective cell in patients with VAP caused by S. aureus.
1. Introduction
Staphylococcus aureus has persisted as an important public
health problem, mostly due to the emergence of strains that
were resistant to methicillin and oxacillin (MRSA) in the
1960s [1]. Ventilator-associated pneumonia (VAP) is themost
frequent infection among patients hospitalized in intensive
care units (ICU), with S. aureus infection being a leading
cause of VAP [2]. VAP maintains high morbidity and mor-
tality. Because of that, a number of inflammatory biomarkers
are under evaluation to guide duration of antibiotic therapy
and to predict disease outcome in VAP, with heterogeneous
results [3–5]. Cell counts of leukocytes subpopulations are
demonstrating to have an important value in predicting
outcome in severe infections [6–8]. Counting leukocytes is
a routine and inexpensive test in ICU settings. We designed
a retrospective study aimed to evaluate the influence of leu-
kocyte subpopulations counts on the probability of death in
patients with VAP caused by S. aureus.
2. Methods
Study Design and Subjects. Data from patients admitted to
the ICU of Hospital Cl´ınico Universitario de Valladolid from
2006 to 2011 with diagnosis of VAP caused by S. aureus were
retrospectively collected for the study (𝑛 = 44). Patients
who were intubated and ventilated in the moment of ICU
2 Mediators of Inflammation
hospitalization and developed VAP were eligible. Patients
who had been treated with corticosteroids or immunosup-
pressive drugs and immunocompromised patients were not
eligible and were excluded from the present study. VAP
was defined as the pneumonia arising more than 72 h after
endotracheal intubation characterized by the presence of
new or progressive radiographic infiltrate associated with
two or more of the following criteria: (a) temperature of
greater than 38.5∘C or less than 36.5∘C, (b) leukocyte count
of greater than 12,000/𝜇L or less than 4,500/𝜇L, (c) purulent
endotracheal aspirate, and (d) positive (≥106 cfu/mL) endo-
tracheal aspirate. Microbiological diagnosis was performed
by quantitative cultures of lower respiratory tract sam-
ples (endotracheal aspirate (BAS) or bronchoscopic alveolar
lavage (BAL)), following the standard protocols for diagnosis
of respiratory bacteria employed in our center. Patients with
positive microbiological identification before 72 first hours
following mechanical ventilation instauration were excluded
because they did not satisfy VAP definition. A standard
survey was employed to collect clinical data and leukogram
counts from the patients. Patient identification remained
anonymous and informed consent was waived due to the
observational nature of the study. Approval of the study
protocol in both the scientific and the ethical aspects was
obtained from the Scientific Committee for Clinical Research
of our hospital.
Statistical Analysis. For the demographic and clinical char-
acteristics of the patients, differences between groups were
assessed using the Chi-squared test for categorical variables
and the Mann-WhitneyU test for continuous variables when
appropriate. We determined the hazard ratio (HR) and 95%
confidence interval by Cox regression analysis, which was
used to assess the impact of eosinophil increments and
counts on mortality over time. Multivariate Cox regression
analysis was performed by using the Wald test for forward
selection. Statistical analysis was performed by using IBM-
SPSS Statistics 20.0.
3. Results
The vast majority of our patients were elderly males, being
hypertension, cardiovascular disease, and smoker habit the
most frequent comorbidities. Both survivors and nonsur-
vivors spent four days under mechanical ventilation and
presented an APACHE-II score of 18 on average. They
were comparable in terms of age, sex, and accompanying
comorbidities.We defined coinfection as those other bacteria
infecting any localization of our patients with clinical signif-
icance. Bacterial coinfection was principally of the following
foci: respiratory, urine, and blood. The principles and most
frequent pathogens isolated were Gram negative rods from
Enterobacteriaceae family (43.3%), Acinetobacter baumannii
(26.7%), and coagulase negative staphylococci (23.3%).
The comparison of cell counts revealed significant lower
eosinophil counts at VAP diagnosis in nonsurvivors (see
Table 1). When cell increments ([counts at VAP diagnosis]–
[counts at ICU admission]) were evaluated in survivors and
nonsurvivors, nonsurvivors showed significant lower incre-
ments of eosinophil counts (𝑃 = 0.010) (see Figure 1(a)).
Potential confounding variables introduced in the multi-
variate Cox regression analysis were age, sex, APACHE-
II score, VAP caused by Staphylococcus aureus methi-
cillin resistance/Staphylococcus aureusmethicillin susceptible
(MRSA/MSSA), bacterial coinfection, and days in mechan-
ical ventilation. For eosinophil increments, the Wald test
selected the APACHE-II score and the eosinophil incre-
ments as the variables associated with mortality: (HR [CI
95%], 𝑃): APACHE-II score: (1.073 [1.001–1.151], 0.050);
(eosinophil increments): (0.996 [0.993–0.999], 0.010). For
total eosinophil counts at VAP diagnosis (log values), the
Wald test selected total eosinophil counts at VAP diagnosis
(log values) as the only variable associated with prognosis:
(HR [CI 95%], 𝑃): (0.370 [0.180–0.750], 0.006). Therefore,
multivariate Cox regression analysis showed that eosinophil
increments as well as total eosinophil counts at VAPdiagnosis
(log values) were protective factors against mortality in
the first 28 days following diagnosis of VAP. Kaplan Meier
analysis showed that patients with eosinophil counts less
than 30 cells/mm3 died earlier (see Figure 1(b)). Area under
the receiver operating characteristic curve (AUROC) analysis
confirmed eosinophil counts at VAP diagnosis as a good test
to diagnose survival (see Figure 1(c)): (area [CI 95%], 𝑃):
(0.701 [0.519–0.882], 0.042).
4. Discussion
Regression studies and AUROCanalysis supported the pro-
tective role of eosinophils in VAP caused by S. aureus.
Eosinophils are granulocytes that develop in the bone mar-
row from pluripotent progenitors. They are released into
the peripheral blood in a phenotypically mature state, and
they are capable of being activated and recruited into tis-
sues in response to appropriate stimuli, most notably the
cytokine interleukin-5 (IL-5) and the eotaxin chemokines
[9]. Eosinophils are recruited to and activated in lung
tissue as part of the pathophysiology of asthma, but recent
findings confirm antimicrobial activities of eosinophils [9].
Catapult-like release of structures resembling neutrophil
extracellular traps (NETs) from eosinophils has been doc-
umented [10]. Our results could in fact support the exis-
tence of an antibacterial activity of the eosinophil in the
severe infection caused by S. aureus. In our patients, fail in
expanding eosinophil counts was translated into a poorer
outcome.
There is increasing evidence on eosinophils as a pro-
tective cell in critically ill patients. Abidi et al. described
eosinopenia as a marker of sepsis on admission to ICU [11].
Recently, these authors have described eosinopenia as an
early marker of increased mortality in critically ill medical
patients [12]. Merino et al. have reported lower eosinophil
counts in patients who died of sepsis than in those who
survived [6]. Prince et al. have demonstrated that S. aureus
𝛼-hemolysin induces cell death in eosinophils [13], which
could represent a microbial mechanism of evasion from host
immune response.
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Table 1: Clinical characteristics of survivors and nonsurvivors.
Survivors (𝑛 = 26) Nonsurvivors (𝑛 = 18) P
Age (years) 60.0 (35.0) 63.5 (26.0) n.s
Sex (male) 23 (88.5) 7 (38.9) n.s
APACHE-II score 17.0 (11.0) 22.0 (12.0) n.s
Days under mechanical ventilation until VAP diagnosis 4.0 (4.0) 4.5 (4.0) n.s
MRSA/MSSA 8 (30.8) 4 (22.2) n.s
Bacterial coinfection (Y/N) 20 (76.9) 10 (55.6) n.s
Diabetes (type I or II) (Y/N) 4 (15.4) 2 (11.1) n.s
Cardiovascular disease (Y/N) 6 (23.1) 5 (27.8) n.s
Chronic renal disease (Y/N) 2 (7.7) 1 (5.6) n.s
Chronic respiratory disease (Y/N) 6 (23.1) 0 (0.0) n.s
Cerebrovascular disease (Y/N) 6 (23.1) 0 (0.0) n.s
Smoker (ever) (Y/N) 8 (30.8) 1 (5.6) n.s
Neurological disease (Y/N) 4 (15.4) 0 (0.0) n.s
Hypertension (Y/N) 12 (46.2) 8 (44.4) 0.084
Hematologic malignancy (ever) (Y/N) 1 (3.8) 0 (0.0) n.s
Cirrhosis of the liver (Y/N) 2 (7.7) 0 (0.0) n.s
Metastatic solid cancer (ever) (Y/N) 0 (0.0) 2 (11.1) 0.018
Gastrointestinal disease (Y/N) 9 (34.6) 1 (5.6) n.s
Chemotherapy (ever) (Y/N) 1 (3.8) 2 (11.1) n.s
Alchohol abuse (Y/N) 4 (15.4) 0 (0.0) n.s
Intravenous drug abuse (Y/N) 2 (7.7) 0 (0.0) n.s
Obesity (Y/N) 3 (11.5) 1 (5.6) n.s
Dyslipidemia (Y/N) 4 (15.4) 2 (11.1) n.s
Lymphocytes at admision to ICU (cells/mm3) 960.9 (1017.3) 812.3 (1336.9) n.s
Monocytes at admision to ICU (cells/mm3) 480.3 (442.9) 465.8 (436.6) n.s
Neutrophils at admision to ICU (cells/mm3) 7801.9 (7053.9) 9504.0 (9101.8) n.s
Basophils at admision to ICU (cells/mm3) 11.5 (22.0) 10.5 (28.0) n.s
Eosinophils at admision to ICU (cells/mm3) 14.9 (119.0) 20.3 (195.0) n.s
Lymphocytes at diagnosis (cells/mm3) 983.0 (734.4) 919.6 (973.1) n.s
Monocytes at diagnosis (cells/mm3) 501.3 (238.2) 707.1 (473.8) n.s
Neutrophils at diagnosis (cells/mm3) 8261.4 (5372.3) 12182.5 (15051.7) n.s
Basophils at diagnosis (cells/mm3) 13.3 (32.3) 14.2 (16.5) n.s
Eosinophils at diagnosis (cells/mm3) 112.2 (231.0) 51.5 (118.8) 0.043
Ratio N/L at admission to ICU 7.2 (9.2) 11.7 (20.1) n.s
Ratio N/L at diagnosis 7.3 (7.6) 10.4 (13.5) 0.059
Survival time was censored at day 28. Continuous variables are expressed as median (interquartile rank). Categorical variables are expressed as n (% over
column). N.s: not significant.
Terradas et al. observed that both sustained eosinopenia
and a high neutrophil to lymphocyte count ratio were
independentmarkers ofmortality in patientswith bacteremia
[8]. Based upon these results, we evaluated the neutrophil to
lymphocyte count ratio in survivors and nonsurvivors. No
differences were found between groups for this ratio although
therewas a trend to exhibit a higher ratio in nonsurvivors (see
Table 1).
A limitation of our study was that only two samples were
collected (at admission and at VAP diagnosis). In further
studies, it will be interesting to assess eosinophil counts in
other extra time points during the disease course.
5. Conclusion
We document here for the first time a protective effect of
eosinophils in patients suffering from VAP caused by S.
aureus. Eosinophil counting is an inexpensive biomarker easy
to implement in clinical practice.
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Figure 1: (a) Box plots showing increments of eosinophil counts: [counts at VAP diagnosis]–[counts at ICU admission] (𝑃 = 0.016). (b)
KaplanMeier curves for survival: deciles from percentile 10 to percentile 90 of eosinophil counts were calculated and used to compare survival
times in those patients with low or high counts. The first decile showing significant differences between groups based upon the log-rank test
was used as the cutoff (percentile 20). Time was censored at 28 days following VAP diagnosis. Cum. survival: cumulative survival. (c) AUROC
analysis: the accuracy and the predictive values of eosinophil counts for detecting survivors in the first 28 days following VAP diagnosis were
assessed calculating the AUROC.
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